Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ackermann (Corvallis, United States of America). Inhaled and small molecules therapeutics to fight respiratory syncytial virus infection in newborn lung. International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments

Member's Comments

No comment yet.

Related content which might interest you: Rhinovirus infections in infants: is respiratory syncytial virus ready for the challenge? Source: Eur Respir J 2008; 32: 249-251 Year: 2008 Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants Source: Eur Respir J 2014; 44: 666-674 Year: 2014 Ribavirin therapy for respiratory syncitial virus infection after lung transplantation Source: Annual Congress 2007 - New insights into clinical lung transplantation Year: 2007 Montelukast is not preventing reactive airway disease in post respiratory syncytial virus bronchiolitis Source: Eur Respir J 2006; 28: Suppl. 50, 757s Year: 2006 Respiratory infections in children: from respiratory syncytial virus to tuberculosis Source: International Congress 2019 – Paediatric Year in review Year: 2019 Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing Source: Eur Respir J 2015; 45: 774-789 Year: 2015 Respiratory syncytial virus infection in childcare and hospitalized children with different respiratory disease severity Source: Annual Congress 2006 - Virus-induced respiratory tract infection Year: 2006 The role of viruses in chronic bronchitis and exacerbations of COPD Source: Eur Respir Monogr 2013; 60: 68-75 Year: 2013 Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model Source: Eur Respir J 2011; 38: 401-408 Year: 2011 DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis Source: Eur Respir J 2001; 18: 734-737 Year: 2001 Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases Source: Eur Respir J 2001; 18: 1044-1058 Year: 2001 Viral infections of the nose and lung Source: ISSN=1025-448x, ISBN=1-904097-19-16, page=79 Year: 2001 Prophylaxis against respiratory syncytial virus in high-risk infants Source: Eur Respir Monogr 2021; 92: 361-371 Year: 2021 Risk factors for bronchial asthma in infants after respiratory syncytial virus infection Source: Annual Congress 2009 - Diagnosis and treatment of viral respiratory infections in early childhood Year: 2009 Cromoglycate in the treatment of respiratory syncytial virus (RSV) bronchiolitis Source: Eur Respir J 2001; 18: Suppl. 33, 169s Year: 2001 Respiratory viral agents in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Experimental induction of respiratory syncytial virus immunopathogenesis in neonatal lambs Source: International Congress 2019 – Understanding the mechanisms underlying airway diseases Year: 2019 RSV and human metapneumovirus – major pathogens of childhood – also adults and the elderly? Source: Annual Congress 2005 - Major viral threats to the lung Year: 2005 Reduced interferon-gamma concentration in infants with severe respiratory syncytial virus bronchiolitis Source: Eur Respir J 2005; 26: Suppl. 49, 27s Year: 2005 Respiratory syncytial virus (RSV) prophylaxis in special populations Source: Annual Congress 2011 - Paediatric epidemiology: bronchiolitis, pneumonia, asthma and spirometry in non-respiratory conditions Year: 2011